遗传性非息肉病性结直肠癌 中国就医指南

Hereditary Nonpolyposis Colorectal Cancer (HNPCC), also known as Lynch syndrome, is an autosomal dominant inherited disorder that predisposes individuals to early-onset colorectal cancer and a spectrum of extracolonic malignancies—including endometrial, gastric, ovarian, small bowel, urinary tract, pancreatic, brain (glioblastoma), and sebaceous gland tumors. Unlike familial adenomatous polyposis (FAP), HNPCC does not involve hundreds to thousands of colonic polyps; instead, patients typically develop only a few adenomas, but these progress rapidly to carcinoma due to defective DNA mismatch repair (MMR). Pathogenesis centers on germline pathogenic variants in MMR genes—most commonly MLH1, MSH2, MSH6, PMS2, and EPCAM (deletion leading to MSH2 silencing). These mutations impair the cell’s ability to correct replication errors, resulting in microsatellite instability (MSI-H), accelerated somatic mutation accumulation, and tumorigenesis. Epidemiologically, Lynch syndrome accounts for approximately 2–4% of all colorectal cancers and affects roughly 1 in 279 individuals in the general population, though underdiagnosis remains widespread. Lifetime colorectal cancer risk ranges from 40% to 80%, depending on the causative gene (highest for MLH1/MSH2), while endometrial cancer risk reaches 25–60% in women. Key risk factors include a family history of early-onset colorectal or endometrial cancer (especially diagnosed before age 50), multiple affected relatives across generations, and personal history of MSI-H tumors. Clinical red flags include colorectal cancer diagnosed under age 50, synchronous or metachronous Lynch-associated cancers, and tumor testing showing MSI-H or loss of MMR protein expression. Beyond oncologic morbidity, HNPCC significantly impacts quality of life: patients face chronic anxiety about cancer development, psychological burden from predictive genetic testing decisions, disruption from intensive surveillance protocols (e.g., colonoscopy every 1–2 years starting at age 20–25), surgical prophylaxis considerations (e.g., risk-reducing hysterectomy/oophorectomy), and potential stigma or familial tension around genetic disclosure. Fertility concerns, sexual health implications post-surgery, and long-term surveillance fatigue further compound psychosocial challenges. Early identification via genetic counseling and testing enables life-saving interventions—yet global access to cascade testing, multidisciplinary care coordination, and culturally competent support remains uneven, particularly outside major academic centers.

# 遗传性非息肉病性结直肠癌（HNPCC/Lynch综合征）治疗与费用指南（消化内科）

一、非手术/保守治疗方案

适用于：基因确诊但未发生肿瘤者（一级预防）、术后辅助或无法耐受手术者。

• •定期内镜监测：结肠镜每1–2年（含染色放大），单次检查费 1,800–3,200元（含病理活检3–5处）；
• •阿司匹林化学预防（600 mg/d，证据等级ⅠA）：年药费 120–300元；
• •MSI/MMR免疫组化+NGS胚系检测（初筛及家系验证）： 4,500–8,000元。

二、手术治疗方案

适用于：已确诊结直肠癌或高级别腺瘤者，强调根治性切除+预防性手术。

• •腹腔镜下根治术（右半/左半/全结肠切除）：手术费 35,000–62,000元，含术前肠镜+增强CT+MRI+CEA/CA19-9等检查 2,800–4,500元；
• •预防性全结肠切除术（携带致病突变且≥25岁、既往腺瘤史）：费用同上，医保报销比例约60%–70%。

三、晚期/复杂/耐药治疗

• •PD-1抑制剂一线治疗（帕博利珠单抗）：200 mg/3周，单周期 17,800元，6周期起始总费用 106,800元；
• •多学科会诊（MDT）及遗传咨询：单次 800–1,500元。

四、方案快速选择指南

• •无癌携带者：优先内镜监测+阿司匹林，年均支出 2,000–4,000元；
• •早期癌患者：腹腔镜根治术为金标准，总费用（含检查） 40,000–70,000元；
• •MSI-H晚期患者：免疫治疗获益显著，首年预算建议 12万–15万元。